greeksoup/ stock research
Stock research / United States / AMGN · Biological Products, (No Diagnostic Substances) · Nasdaq

Amgen Inc. (AMGN)

Amgen discovers, develops, manufactures and delivers medicines, and it operates in one segment, human therapeutics, with a presence in approximately 100 countries. It was incorporated in California in 1980 and became a Delaware corporation in 1987. The filing says the company helped launch the biotechnology industry more than 45 years ago. Product sales in 2025 split 73 percent to the United States and 27 percent to the rest of the world, the same split as 2024.

Amgen Inc.

Amgen discovers, develops, manufactures and delivers medicines, and it operates in one segment, human therapeutics, with a presence in approximately 100 countries. It was incorporated in California in 1980 and became a Delaware corporation in 1987. The filing says the company helped launch the biotechnology industry more than 45 years ago. Product sales in 2025 split 73 percent to the United States and 27 percent to the rest of the world, the same split as 2024.

The main medicines

Prolia, launched in the United States and Europe in 2010, is used mainly for osteoporosis in postmenopausal women at high risk of fracture and to increase bone mass in men with osteoporosis at high risk of fracture. XGEVA contains the same active ingredient but is approved for different indications, patient populations, dose and frequency of administration. Repatha, a PCSK9 inhibitor launched in 2015, reduces the risk of major adverse cardiovascular events in adults at increased risk of them, and lowers LDL cholesterol in adults with primary hyperlipidemia. In August 2025 the FDA broadened Repatha's approved use to adults at increased cardiovascular risk from uncontrolled LDL cholesterol, removing the requirement for a prior cardiovascular disease diagnosis, and in November 2025 the company reported Phase 3 VESALIUS-CV results showing a 25 percent relative reduction in a composite of coronary heart disease death, heart attack or ischemic stroke in high-risk adults without a prior heart attack or stroke. Otezla, acquired from Bristol Myers Squibb in November 2019, is an oral small molecule that inhibits PDE4, approved for plaque psoriasis, active psoriatic arthritis, oral ulcers associated with Behçet's disease, and paediatric plaque psoriasis. ENBREL is a tumour necrosis factor blocker. Other marketed products include EVENITY, BLINCYTO, TEZSPIRE, KYPROLIS, KRYSTEXXA, TEPEZZA, UPLIZNA and IMDELLTRA. The filing states that UPLIZNA, approved by the FDA in April 2025 for Immunoglobulin G4-related disease, is the first and only approved treatment for adults living with that disease.

Patents running out, and biosimilars both ways

Several patents on the principal products have expired and the company faces competition from biosimilars and generics. Versions of EPOGEN, NEUPOGEN, Neulasta and ENBREL in Canada have launched, and United States ENBREL biosimilars are approved but not launched. The RANKL antibody patents behind Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select countries in Europe, and the company states that it expects accelerated sales erosion as multiple biosimilars have launched. It sells biosimilars of its own too: eight launched since 2018, including WEZLANA, a biosimilar to STELARA, and BKEMV, a biosimilar to SOLIRIS, both in the United States in 2025.

How the medicines reach patients

The largest concentration of sales and marketing people is in the United States and Europe, with other territories covered through the company's own affiliates, acquired businesses or product rights, and collaborations. In the Asia Pacific region it sells in partnership with Astellas Pharma, BeOne, Mitsubishi Tanabe Pharma, Takeda and Kyowa Kirin. Products are marketed to healthcare providers including physicians and their clinics, dialysis centres, hospitals and pharmacies, and some are marketed direct to patients through print, television and online media. In the United States substantially all sales go to pharmaceutical wholesale distributors. Three of those distributors, McKesson, Cencora and Cardinal Health, each individually accounted for more than a tenth of total revenues in 2025, 2024 and 2023, and together they were 77 percent of worldwide gross revenues in 2025.

Manufacturing

The products are both biologics and small molecule drugs, with the majority being biologics produced in living cells, which the filing describes as inherently complex because of naturally occurring molecular variations. The filing also states that the company believes it is a leader in the manufacture of biologics and that this represents a competitive advantage. Newer biomanufacturing facilities in North Carolina and Ohio were built at lower cost and with greater speed than traditional facilities, the North Carolina site using portable and smaller equipment so that different medicines can be made simultaneously, and both sites carry on-site photovoltaic renewable generation. In 2025 the company announced expansions of its manufacturing network in New Albany, Ohio and in Puerto Rico, and broke ground on a research and development facility in Thousand Oaks, California.

From Amgen's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Amgen became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 4 November 2026
Revenue
$10.4 billion
+8.5% on the year · +3.1% on the quarter
Q4 FY2024Q3 FY2026
Net income
$3.9 billion
+20.1% on the year · +62.7% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$7.08
+19.4% on the year · +62.0% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 13 February 2026
Revenue
$36.8 billion
+10.0% on the year
FY2018FY2025
Net income
$7.7 billion
+88.5% on the year
FY2018FY2025
Diluted EPS
$14.23
+88.2% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsAmgen (AMGN) reported revenue of $36.8 billion for fiscal 2025, the year ended 31 December 2025, up 10.0% on the year before. Net income was $7.7 billion and diluted earnings per share $14.23. Revenue was $33.4 billion in fiscal 2024, $28.2 billion in fiscal 2023, $26.3 billion in fiscal 2022 and $26.0 billion in fiscal 2021. Net income in the same years was $4.1 billion, $6.7 billion, $6.6 billion and $5.9 billion. Over the twelve months to 30 September 2026, Amgen reported revenue of $38.9 billion and net income of $9.4 billion. Revenue grew 7.6% a year, compounded, over the five years to fiscal 2025. Amgen declared $10.08 a share in dividends over the last four quarters and had 541 million shares outstanding at the latest filed count. At 30 September 2026 it carried $54.0 billion of debt and $13.2 billion of cash. At the close of 6 November 2026 the market cap of Amgen was $249.0 billion, 26.7 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE65.4%
ROCE18.4%
Operating margin32.4%
Net margin24.1%
FCF margin24.6%
Interest cover4.8x
Debt to equity3.76x
Cash conversion1.28x
Share count, last 12 months0.4%
Sales CAGR, 3 years11.8%
Profit CAGR, 3 years5.6%
EPS, TTM$17.24

At the close of 6 November 2026

Price$460.33
Market cap$249.0 billion
Stock P/E26.7x
Price to book17.4x
EV / EBITDA18.9x
Dividend yield2.2%
Market cap / sales6.4x
52-week high$478.33
52-week low$313.85
Price, 1 year45.9%
Price CAGR, 3 years19.3%
Price CAGR, 5 years16.6%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Amgen Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
AMGNgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue6,8466,2386,5946,6526,8396,1056,9866,9038,1967,4478,3888,5039,0868,1499,1799,5579,8668,61810,05410,365
Cost of revenue1,7181,5611,5101,5881,7471,7201,8131,8063,1123,2003,2363,3103,1122,9683,0113,0822,9762,7442,8112,788
Gross profit5,1284,6775,0845,0645,0924,3855,1735,0975,0844,2475,1525,1935,9745,1816,1686,4756,8905,8747,2437,577
Gross margin75%75%77%76%74%72%74%74%62%57%61%61%66%64%67%68%70%68%72%73%
R&D1,3489591,0391,1121,3241,0581,1131,0791,5341,3431,4471,4501,7241,4861,7441,9002,1421,7191,8682,111
SG&A1,4251,2281,3271,2871,5721,2581,2941,3532,2741,8081,7851,6251,8781,6871,6911,7201,9521,6021,7451,680
Operating income2,3042,5002,1762,6602,2301,9212,6842,0211,2719911,9092,0472,3111,1782,6562,5262,7202,6663,5143,710
Operating margin34%40%33%40%33%31%38%29%16%13%23%24%25%14%29%26%28%31%35%36%
Interest expense335295328368415543752759821824808776747723694685653657673653
Pre-tax income2,1311,6751,5312,3921,7483,4421,6141,947852-68.07943,1017821,9731,5683,9211,5142,0842,7684,686
Tax rate11%12%14%10%8%17%15%11%10%n/a6%9%20%12%9%18%12%13%14%18%
Net income1,8991,4761,3172,1431,6162,8411,3791,730767-1137462,8306271,7301,4323,2161,3331,8192,3753,864
Net margin28%24%20%32%24%47%20%25%9%-2%9%33%7%21%16%34%14%21%24%37%
Diluted EPS$3.33$2.68$2.45$3.98$3.00$5.28$2.57$3.22$1.42-$0.21$1.38$5.22$1.16$3.20$2.65$5.93$2.45$3.34$4.37$7.08
Operating cash flow2,8082,1641,9302,9782,6491,0644,1092,7605386892,4593,5714,7711,3912,2804,6841,6032,1894,0024,241
Capital expenditure287190246160340344271248249230238257371411369436642712513587
Free cash flow2,5211,9741,6842,8182,3097203,8382,5122894592,2213,3144,4009801,9114,2489611,4773,4893,654
Buybacks1,4436,3600.00.00.00.00.00.00.0n/an/an/an/an/an/an/an/an/an/an/a
Dividends paid9901,0801,0381,0381,0401,1371,1391,1401,1401,2081,2091,2101,2051,2791,2801,2821,2831,3581,3621,363
Shares outstanding558m534m535m534m534m534m535m535m535m536m537m538m537m538m538m538m539m540m541m541m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue14,77115,00314,64215,05315,58217,26518,67620,06321,66222,99122,84923,74723,36225,42425,97926,32328,19033,42436,75138,903
Cost of revenuen/an/an/an/a2,7083,1993,3464,4224,2274,1624,0694,1014,3566,1596,4546,4068,45112,85812,03711,319
Gross profitn/an/an/an/a12,87414,06615,33015,64117,43518,82918,78019,64619,00619,26519,52519,91719,73920,56624,71427,584
Gross marginn/an/an/an/a82.6%81.5%82.1%78.0%80.5%81.9%82.2%82.7%81.4%75.8%75.2%75.7%70.0%61.5%67.2%70.9%
Research and development3,2663,0302,8642,8943,1673,3804,0834,2974,0703,8403,5623,7374,1164,2074,8194,4344,7845,9647,2727,840
Selling, general and administrative3,3613,7893,8203,9834,4994,8145,1844,6994,8465,0624,8705,3325,1505,7305,3685,4146,1797,0967,0506,979
Operating income3,9805,2145,5065,5454,3125,5775,8676,1918,4709,7949,97310,2639,6749,1397,6399,5667,8977,2589,08012,610
Operating margin26.9%34.8%37.6%36.8%27.7%32.3%31.4%30.9%39.1%42.6%43.6%43.2%41.4%35.9%29.4%36.3%28.0%21.7%24.7%32.4%
Interest expense4965515786046101,0531,0221,0711,0951,2601,3041,3921,2891,2621,1971,4062,8753,1552,7552,636
Pre-tax income3,7935,0155,2045,3174,1505,0095,2655,5857,9789,1639,5979,5459,1388,1336,7017,3467,8554,6098,97611,052
Income tax7159635996904676641844271,0391,4417,6181,1511,2968698087941,1385191,2651,661
Effective tax rate18.9%19.2%11.5%13.0%11.3%13.3%3.5%7.6%13.0%15.7%79.4%12.1%14.2%10.7%12.1%10.8%14.5%11.3%14.1%15.0%
Net income3,0784,0524,6054,6273,6834,3455,0815,1586,9397,7221,9798,3947,8427,2645,8936,5526,7174,0907,7119,391
Net margin20.8%27.0%31.5%30.7%23.6%25.2%27.2%25.7%32.0%33.6%8.7%35.3%33.6%28.6%22.7%24.9%23.8%12.2%21.0%24.1%
Diluted EPS$2.74$3.77$4.51$4.79$4.04$5.52$6.64$6.70$9.06$10.24$2.69$12.62$12.88$12.31$10.28$12.11$12.49$7.56$14.23$17.24
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by product or service FY2017 to FY2025

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Other products2,5835,572n/an/a5,7105,0504,6965,6307,26319.8%
Prolia1,9682,291n/an/a3,2483,6284,0484,3744,41412.0%
Repathan/a550n/an/a1,1171,2961,6352,2223,0168.2%
Otezlan/a0n/an/a2,2492,2882,1882,1262,2656.2%
ENBREL5,4335,014n/an/a4,4654,1173,6973,3162,2266.1%
EVENITYn/an/an/an/a5307871,1601,5632,1005.7%
XGEVA1,5751,786n/an/a2,0182,0142,1122,2252,0845.7%
TEPEZZAn/an/an/an/a004481,8511,9035.2%
Other revenues1,0541,2141,1581,1841,6821,5221,2801,3981,6034.4%
BLINCYTOn/an/an/an/a4725838611,2161,5594.2%
Nplaten/an/an/an/a1,0271,3071,4771,4561,5244.1%
TEZSPIREn/an/an/an/an/a1705679721,4784.0%
KYPROLIS835968n/an/a1,1081,2471,4031,5031,4123.8%
Aranesp2,0531,877n/an/a1,4801,4211,3621,3421,3893.8%
KRYSTEXXAn/an/an/an/a002721,1851,3403.6%
Vectibixn/an/an/an/a8738939841,0451,1753.2%
EPOGEN® (epoetin alfa)1,096n/an/an/an/an/an/an/an/an/a
Neulasta® (pegfilgrastim)4,5344,475n/an/an/an/an/an/an/an/a
Productn/an/a22,20424,240n/an/an/an/an/an/a
Sensipar® / Mimpara® (cinacalcet)1,718n/an/an/an/an/an/an/an/an/a
Other products FY2017 to FY2025Prolia FY2017 to FY2025Repatha FY2018 to FY2025Otezla FY2021 to FY2025ENBREL FY2017 to FY2025EVENITY FY2021 to FY2025XGEVA FY2017 to FY2025Product FY2019 to FY2020Neulasta® (pegfilgrastim) FY2017 to FY2018Sensipar® / Mimpara® (cinacalcet) FY2017EPOGEN® (epoetin alfa) FY2017Other
22.8FY201723.4FY201926.0FY202128.2FY202336.8FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by region FY2011 to FY2025

FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States11,98513,41514,48015,39617,16718,32618,02918,35817,22418,49618,19418,59519,80623,86326,41971.9%
ROWn/an/an/an/an/a4,6654,8205,3896,1386,9287,7857,7288,3849,56110,33228.1%
Rest of the world (ROW)3,5973,8504,1964,6674,495n/an/an/an/an/an/an/an/an/an/an/a
United StatesROW FY2016 to FY2025Rest of the world (ROW) FY2011 to FY2015
15.6FY201118.7FY201321.7FY201522.8FY201723.4FY201926.0FY202128.2FY202336.8FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008FY2009FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow5,4015,9886,3365,7875,1195,8826,5268,9529,73110,35411,17711,2969,15010,4979,2619,7218,47111,4909,95812,035
Capital expenditure1,2676725305805676896937185947386647386186088809361,1121,0961,8582,454
Free cash flow4,1345,3165,8065,2074,5525,1935,8338,2349,1379,61610,51310,5588,5329,8898,3818,7857,35910,3948,1009,581
Free cash flow margin28.0%35.4%39.7%34.6%29.2%30.1%31.2%41.0%42.2%41.8%46.0%44.5%36.5%38.9%32.3%33.4%26.1%31.1%22.0%24.6%
Cash from investing-1,992-3,165-3,202-4,152-786-9,990-8,469-5,752-5,547-8,658-4,02414,3395,709-5,401733-6,044-26,204-1,046-1,943-2,627
Cash from financing-2,668-3,073-2,024-1,232-6744192,491-3,274-3,771-2,599-6,594-22,490-15,767-4,867-8,271-4,03721,048-9,415-10,859-5,663
Depreciation and amortisation1,2021,0731,0491,0171,0601,0881,2862,0922,1082,1051,9551,9462,2063,6013,3983,4174,0715,5925,1672,703
Share-based compensation263262284353341362403408322311329311308330341401431530494493
Buybacks5,1002,2683,2083,7868,3154,6078321381,8672,9653,16017,7947,7023,4864,9756,3600.02000.0n/a
Dividends paidn/an/a0.00.05001,1181,4151,8512,3962,9983,3653,5073,5093,7554,0134,1964,5564,8325,1245,366
Dividend per sharen/an/an/an/an/an/an/an/an/a$4.15$4.77$5.41$5.95$6.56$7.22$7.95$8.64$9.13$9.66$9.94
Diluted shares, weighted1,123m1,075m1,021m965m912m787m765m770m766m754m735m665m609m590m573m541m538m541m542m546m
Shares outstanding at period endn/a1,047m995m932m796m756m755m760m754m738m722m630m591m578m558m534m535m537m539m541m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity18,51220,88522,66723,94419,02919,06022,09625,77828,08329,87525,24112,5009,6739,4096,7003,6616,2325,8778,65814,352
Debtn/a4,09510,60113,36221,42826,52932,12830,58831,42934,59635,34233,92929,90332,98633,30938,94564,61360,09954,60454,007
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a388306525539691673696n/a
Other liabilitiesn/a11,4476,3616,1808,4148,70911,90112,64312,06413,15519,37119,98719,74320,24720,63121,97625,61825,19026,62827,689
Total liabilities and equityn/a36,42739,62943,48648,87154,29866,12569,00971,57677,62679,95466,41659,70762,94861,16565,12197,15491,83990,58696,048
Owned
Fixed assetsn/a5,8795,7385,5225,4205,3265,3495,2234,9074,9614,9894,9584,9284,8895,1845,4275,9416,5437,9138,884
Goodwilln/a11,33911,33511,33411,75012,66214,96814,78814,75114,75114,76114,69914,70314,68914,89015,52918,62918,63718,68018,664
Intangible assetsn/a2,9882,5672,2302,5843,96813,26212,69311,64110,2798,6097,44319,41316,58715,18216,08032,64127,69922,27619,536
Investmentsn/a7,77810,55814,13513,69520,80415,59623,29527,23834,84437,87822,3592,8744,38148.01,6760.0n/an/an/a
Securities held for sale or to maturityn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a11,4868,52512,621
Cash and equivalents2,0241,7742,8843,2876,9463,2573,8053,7314,1443,2413,8006,9456,0376,2667,9897,62910,94411,9739,12913,190
Receivablesn/a2,0732,1092,3352,8962,5182,6972,5462,9953,1653,2373,5804,0574,5254,8955,5637,2686,7829,57010,353
Inventoryn/a2,0752,2202,0222,4842,7443,0192,6472,4352,7452,8342,9403,5843,8934,0864,9309,5186,9986,2256,389
Other assetsn/a2,5212,2182,6213,0963,0197,4294,0863,4653,6403,8463,4924,1117,7188,8918,28712,2131,7218,2686,411
Total assetsn/a36,42739,62943,48648,87154,29866,12569,00971,57677,62679,95466,41659,70762,94861,16565,12197,15491,83990,58696,048
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded5.4%7.6%11.8%8.2%
Profit growth, compounded1.1%1.2%5.6%34.1%
Return on equity, average79.2%106.7%88.8%89.1%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Amgen's revenue in fiscal 2025?

Amgen (AMGN) reported revenue of $36.8 billion for fiscal 2025, the year ended 31 December 2025, up 10.0% on the year before.

How much did Amgen earn in fiscal 2025?

Net income was $7.7 billion for fiscal 2025, and diluted earnings per share $14.23.

What is Amgen's P/E ratio?

At the close of 6 November 2026, Amgen traded at 26.7 times its earnings over the twelve months to 30 September 2026.

What is Amgen's market cap?

The market cap of Amgen was $249.0 billion at the close of 6 November 2026.

Does Amgen pay a dividend?

Yes. Amgen declared $10.08 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
38 companies share its SEC industry code (Biological Products, (No Diagnostic Substances)); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on AMGN

Dividends$10.08 a share over the four quarters to 30 September 2026, a 2.19% yield
Filings24 in twelve months: 11 current reports (8-K), about 4 results of operations; 3 officer or director change; 1 material cybersecurity incident; 1 shareholder vote; 1 material agreement
Planned insider sales10 Form 144 notices in twelve months, $29.3 million; latest 13 August 2026
Options tapeput/call 0.86 by open interest at the 6 November 2026 close; the straddle prices a 3.5% move to 13 November 2026
13F holders3,174 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading14 sales and 0 purchases on Form 4 in twelve months
Congress3 House trades disclosed in six months
Short interest13.4 million shares short, 4.97 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20264 November 2026EDGAR
10-Q30 June 20265 August 2026EDGAR
10-Q31 March 20261 May 2026EDGAR
10-K31 December 202513 February 2026EDGAR
10-Q30 September 20255 November 2025EDGAR
10-Q30 June 20256 August 2025EDGAR
10-Q31 March 20252 May 2025EDGAR
10-K31 December 202414 February 2025EDGAR
10-Q30 September 202431 October 2024EDGAR
10-Q30 June 20247 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.